Semaglutide,
explained in depth.

Semaglutide is a synthetic peptide that mimics the human hormone GLP-1 (glucagon-like peptide-1). GLP-1 is an incretin hormone naturally produced in the gut after eating. It tells the pancreas to release insulin, tells the liver to stop producing glucose, slows gastric emptying so food moves through the stomach more slowly, and signals the brain's appetite centers to reduce hunger. The problem with natural GLP-1 is that the body breaks it down within minutes — it has a half-life of roughly 2 minutes, making it useless as a medication.

Semaglutide solves this by modifying the GLP-1 molecule at three key positions. A substitution at position 8 prevents the enzyme DPP-4 from cleaving the peptide. A substitution at position 34 ensures a fatty acid chain attaches at the correct location. And a C-18 fatty diacid side chain at position 26 allows semaglutide to bind to albumin — a protein circulating in the bloodstream — which shields it from degradation and dramatically extends its half-life to approximately 7 days. That weekly half-life is why semaglutide can be dosed once per week as a subcutaneous injection, or once daily in oral form.

The clinical data on semaglutide comes from two major trial programs. The SUSTAIN trials (2015–2020, seven trials, over 8,000 patients) studied semaglutide for type 2 diabetes and established its ability to lower A1C levels by 1.5–1.8 percentage points on average. The STEP trials (2020–2024, five major trials, over 15,000 patients) studied semaglutide at a higher dose (2.4 mg weekly) specifically for chronic weight management and found average body weight reductions of 15–17% over 68 weeks in adults with obesity — making semaglutide the most effective single-agent weight loss medication documented in randomized controlled trials.

Semaglutide drives weight loss through three overlapping mechanisms. First, it acts on GLP-1 receptors in the hypothalamus — the brain region that regulates appetite — to reduce hunger and increase the feeling of satiety. Patients on semaglutide consistently report that they think about food less frequently and feel full faster when eating. Second, semaglutide slows gastric emptying, meaning food stays in the stomach longer after a meal, which extends the sensation of fullness for hours. Third, semaglutide improves insulin sensitivity and glucose regulation, which reduces the blood sugar crashes that trigger cravings and binge eating.

The weight loss results from the STEP clinical trials are the reason semaglutide has dominated the weight management landscape. In STEP 1 (2021), adults with obesity who received semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. STEP 2 studied patients with both type 2 diabetes and obesity and found 9.6% weight loss — lower than STEP 1, likely because diabetes itself makes weight loss harder. STEP 3 combined semaglutide with intensive behavioral therapy and achieved 16% average weight loss. STEP 5 extended the treatment period to 104 weeks and confirmed that weight loss was sustained as long as the medication was continued. For a deeper breakdown of the clinical trial data and practical timelines, see the semaglutide for weight loss page.

Before semaglutide became famous as a weight loss medication, it was developed and approved for type 2 diabetes. The SUSTAIN trial program studied semaglutide at lower doses (0.5 mg and 1.0 mg weekly) across seven major trials involving over 8,000 patients. The results established semaglutide as one of the most effective single agents for A1C reduction: patients consistently saw A1C drop by 1.5 to 1.8 percentage points, which is a meaningful clinical improvement for most people with type 2 diabetes.

Beyond glucose control, the SUSTAIN-6 trial showed a cardiovascular benefit — semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 26% compared to placebo. This cardiovascular outcome finding was significant because many older diabetes medications either had no cardiovascular benefit or, in some cases, increased cardiovascular risk. Semaglutide has since become a first-line recommendation in multiple treatment guidelines for type 2 diabetes patients with cardiovascular risk factors. See the full semaglutide for type 2 diabetes analysis for trial-by-trial breakdowns.